ＲＳＶの処置のための組合せ製品

Japanese Patent JP7065030

B2

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione , for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B - or the pharmaceutical product comprising Compound A and one or more Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

JPWO2005030737	Phenylene derivative having a tetrazole ring or a thiazolidinedione ring
WO/2006/064757	AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF
WO/2001/007015	QUICK-RELEASE EXTRUDATES, METHOD FOR PREPARING THE SAME AND COMPOSITIONS OBTAINED FROM SAID EXTRUDATES

Nise Issebad
Goy Barts, Nele Ether E.
Royman's, Dark Andrey.
Cole, Anil

JP2018540796A

May 11, 2022

February 02, 2017

Click for automatic bibliography generation  

Janssen Sciences Ireland Unlimited Company

A61K31/437; A61K31/41; A61K31/4745; A61K31/519; A61K31/55; A61K31/5513; A61K31/7056; A61K39/395; A61P31/14; A61P43/00

JP2014503525A

WO2016055791A1
WO2014174018A1
WO2015026792A1

Antiviral Research,2003年,Vol.60, No.1,p.51-59
Antimicrobial Agents and Chemotherapy,2015年12月14日,Vol.60, No.3,p.1264-1273
The NEW ENGLAND JOURNAL of MEDICINE,2014年,Vol.371, No.8,p.711-722
MEJIAS ASUNCION,NEW OPTIONS IN THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS DISEASE,JOURNAL OF INFECTION,2015年04月25日,VOL:71,PAGE(S):S80-S87,http://dx.doi.org/10.1016/j.jinf.2015.04.025
DRUGS OF THE FUTURE,2015年,Vol.40, No.11,p.765-766
WORLD JOURNAL OF PEDIATRICS,2010年,Vol.6, No.4,p.296-300
JOURNAL OF VIROLOGY,2005年,Vol.79, No.20,p.13105-13115
XIONG HUI; FOULK MELINDA; ET AL,DISCOVERY OF A POTENT RESPIRATORY SYNCYTIAL VIRUS RNA POLYMERASE INHIBITOR,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,PERGAMON,2013年10月16日,VOL:23, NR:24,PAGE(S):6789 - 6793,http://dx.doi.org/10.1016/j.bmcl.2013.10.018

Hiroshi Kobayashi
Eiji Katayama
Norio Omori
Yasuhito Suzuki

Previous Patent: Aryldiamine compounds and organic electroluminescence devices

Next Patent: Electrical energy transmission equipment